Thelansis

  Small cell prostate carcinoma (SCPC), constituting less than 0.5% to 1% of all prostate cancers, is an uncommon variant of high-grade neuroendocrine carcinoma occurring outside the lungs. It exhibits an aggressive clinical course and carries a dismal prognosis. Following one round of chemotherapy, the patient's condition deteriorated, with the disease progressing and metastatic burden intensifying. Identifying the primary site of metastatic SCNEC can pose a challenge. While SCNEC is predominantly found in the lungs, accounting for a significant majority, approximately 10% of extrapulmonary SCNEC cases manifest in the prostate. Both lung and prostate metastases frequently involve the liver. SCNECP typically emerges in patients previously subjected to androgen deprivation therapy (ADT) for conventional prostate adenocarcinoma (CPAC), who subsequently experience disease recurrence, transitioning to castrate-resistant prostate cancer. Thelansis’s “Metastatic Small Cell Neuroendo